Ranbaxy AIDS Drugs Suspended From U.S. Program
This article was originally published in PharmAsia News
Executive Summary
The President's Emergency Plan for AIDS Relief has suspended funding for three Ranbaxy generic drugs, in the wake of U.S. FDA issuing an import alert and two warning letters citing GMP deficiencies at Ranbaxy plants in Paonta Sahib and Dewas, India. The three HIV drugs - zidovudine, lamivudine and nevirapine - are manufactured at the Panota Sahib plant. The U.S. program, which supplies medicines to developing countries, paid $8.9 million for Ranbaxy AIDS drugs last fiscal year. (Click here for more